HP-beta-CD restores cholesterol homeostasis in NPC1
PrimaryTrappsol Cyclo, an intravenous hydroxypropyl-beta-cyclodextrin (HP-beta-CD), is proposed to affect Niemann-Pick Disease Type C1 by acting on cholesterol metabolism and homeostasis in peripheral tissues, including liver, and in the central nervous system. The causal theory is that NPC1 pathology is driven in part by disrupted intracellular cholesterol handling, and that systemic HP-beta-CD can modify this biology enough to stabilize or slow disease progression. Testable predictions are that treated patients should show pharmacodynamic changes in cholesterol synthesis or breakdown biomarkers, CNS cholesterol-metabolism markers such as 24S-hydroxycholesterol, and clinical stabilization or improvement on NPC severity domains rather than the expected progressive decline.
Popperian evaluation
The premise is strong. NPC1 is a cholesterol-trafficking disease, and the theory starts from a credible defect: disrupted intracellular cholesterol handling. HP-beta-CD also has a plausible mechanistic link because preclinical work and the Phase I/II trial frame it as acting on cholesterol metabolism in peripheral tissues and the CNS. The weakest point is delivery. Intravenous HP-beta-CD was detected in CSF in 5 patients who had serial lumbar punctures, but detection alone does not prove enough CNS exposure to change neuronal disease biology.
Supporting evidence: NPC1 pathology is described as driven in part by disrupted intracellular cholesterol handling and loss of cholesterol homeostasis.; Preclinical studies reported a role for systemically administered HP-beta-CD in cholesterol metabolism and homeostasis in peripheral tissues, including liver, and in the CNS.; HP-beta-CD was detected in CSF in patients after intravenous dosing.
Counter evidence: The CNS exposure claim remains partly inferential because CSF detection does not by itself establish biologically sufficient drug levels in the relevant brain compartments.; The theory depends on the assumption that modifying cholesterol handling can slow the broader neurodegenerative course of NPC1.
The theory explains several observations in the expected direction: biomarker-focused pharmacodynamics, CSF detection, and clinical stabilization or improvement over 48 weeks. The problem is causal separation. The trial had 12 randomized patients, all received HP-beta-CD, 9 completed, and there was no placebo or external control arm. Eight of 9 completers improved in at least two 17D-NPC-CSS domains, which is encouraging in a progressive disease, but completer selection, natural variability, physician expectation, regression to the mean, and placebo-linked reporting can still explain part of the signal.
Supporting evidence: The trial measured cholesterol synthesis and breakdown products, PPCS, CSF neurodegeneration markers, CNS inflammation markers, and 24S-hydroxycholesterol.; Eight of 9 patients who completed 48 weeks improved in at least two domains of the 17D-NPC Clinical Severity Scale.; Seven of 9 completers were judged by treating physicians to have improved to some degree, and 2 remained stable.
Counter evidence: All patients received HP-beta-CD, so the trial cannot cleanly separate treatment effect from background variability or expectation effects.; Three patients discontinued, all in the 1500 mg/kg group, leaving the clinical improvement analysis focused on completers.; Treating-physician global impressions are vulnerable to bias in an uncontrolled study.
The theory is clearly testable. It predicts measurable changes in cholesterol synthesis or breakdown biomarkers, CNS cholesterol markers such as 24S-hydroxycholesterol, and clinical stabilization or improvement instead of progressive decline. A controlled trial could break the theory cleanly: no pharmacodynamic shift, no CSF-relevant signal, or clinical decline matching untreated NPC1 would count against it.
Supporting evidence: The theory predicts pharmacodynamic changes in cholesterol synthesis or cholesterol breakdown biomarkers.; It predicts changes in CNS cholesterol-metabolism markers such as 24S-hydroxycholesterol.; It predicts clinical stabilization or improvement on NPC severity domains rather than expected progressive decline.
Counter evidence: The current evidence does not define exact biomarker thresholds that would count as sufficient target engagement.; Clinical stabilization in NPC1 needs a well-specified comparator because disease tempo varies across patients.
Reasoning tree
Public endorsements
The evidence provided does not contain any quote, statement, or publication from Howard S about the NPC1 cholesterol-homeostasis theory behind Trappsol Cyclo. The records describe company trial milestones and personnel news, but they do not show him publicly endorsing, discussing, or disputing the mechanism.